Scott G. Lamont

发表

Amine-promoted, organocatalytic aziridination of enones.

A. Armstrong, C. Baxter, Andrew R. Pape, 2007, Organic letters.

Aspects of stereocontrol in the L-Selectride reduction of 4-acyl-1,3-dioxolane derivatives

S. Lamont, J. Robertson, W. Unsworth, 2010 .

Rhodium(II)-catalysed tandem aziridination and ring-opening: stereoselective synthesis of functionalised tetrahydrofurans.

Thomas O. Ronson, S. Lamont, J. Robertson, 2014, Chemical communications.

Substrate scope and stereocontrol in the Rh(II)-catalysed oxyamination of allylic carbamates

J. Robertson, W. Unsworth, Scott G. Lamont, 2014 .

Stereospecificity in the Au-catalysed cyclisation of monoallylic diols. Synthesis of (+)-isoaltholactone.

S. Lamont, J. Robertson, W. Unsworth, 2011, Chemical communications.

Hydantoin based inhibitors of MMP13--discovery of AZD6605.

R. Maciewicz, K. Page, J. Bowyer, 2013, Bioorganic & medicinal chemistry letters.

Flexible access to conformationally-locked bicyclic morpholines.

S. Lamont, J. Parkinson, W. Kerr, 2013, Chemical communications.

Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C.

Doyle J Cassar, Nichola L. Davies, J. Breed, 2022, Journal of medicinal chemistry.

Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant GTPase KRASG12C.

Doyle J Cassar, J. Breed, D. Ogg, 2020, Journal of medicinal chemistry.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Peter Ballard, Simon J Brown, Nathaniel G. Martin, 2014, Journal of medicinal chemistry.

Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma.

Nichola L. Davies, A. Ferguson, L. Drew, 2017, Journal of medicinal chemistry.

N-amino-N-methylmorpholinium salts : Highly active aziridination reagents for chalcones

A. Armstrong, D. Carbery, Andrew R. Pape, 2006 .

N‐Amino‐N‐methylmorpholinium Salts: Highly Active Aziridination Reagents for Chalcones.

A. Armstrong, D. Carbery, Andrew R. Pape, 2007 .

Discovery of a potent and selective oral inhibitor of ERK1/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of non-small cell lung cancer (NSCLC).

J. Breed, M. Anderton, Lyman J. L. Feron, 2019, Journal of medicinal chemistry.

Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.

J. Debreczeni, Lyman J. L. Feron, Michael Tonge, 2017, Journal of medicinal chemistry.

Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3.

J. Debreczeni, A. Turnbull, S. Degorce, 2015, Journal of medicinal chemistry.

Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.

Rhys D O Jones, A. Rabow, G. Walker, 2013, Bioorganic & medicinal chemistry letters.

Optimization of a Series of Potent, Selective and Orally Bioavailable SYK Inhibitors.

David M. Wilson, Peng-Fei Wang, S. Fawell, 2009, Bioorganic & medicinal chemistry letters.

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

A. Rabow, D. M. Andrews, G. Walker, 2015, Journal of medicinal chemistry.

Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.

J. Debreczeni, J. G. Cumming, S. Wells, 2015, Journal of medicinal chemistry.

Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.

Peng-Fei Wang, J. Patel, B. Barlaam, 2020, Bioorganic & medicinal chemistry letters.

Sulfenyl Ynamides in Gold Catalysis: Synthesis of Oxo‐functionalised 4‐aminoimidazolyl Fused Compounds by Intermolecular Annulation Reactions

S. Lamont, P. Davies, E. Arce, 2020, Advanced Synthesis & Catalysis.

Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.

Paul R. J. Davey, James S. Scott, A. Bailey, 2019, Journal of medicinal chemistry.

Regioselective ortho alkylation of nitro indole, carbazole, benzothiophene and benzofuran

S. Groombridge, J. Feron, Craig S. Donald, 2015 .

Synthesis of trans 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3H-pyrazolo [4,3-f]isoquinolines using a Pictet-Spengler approach

James S. Scott, A. Bailey, T. Moss, 2018, Tetrahedron Letters.

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).

C. A. Roberts, A. Rabow, M. Waring, 2016, Journal of medicinal chemistry.

The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.

Chris Davies, S. Gerhardt, David J. Milne, 2011, Bioorganic & medicinal chemistry letters.

Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration.

Doyle J Cassar, Nichola L. Davies, J. Breed, 2023, Journal of medicinal chemistry.

Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.

Peter D Smith, Chris Davies, S. Lamont, 2011, Bioorganic & medicinal chemistry letters.